Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
Enrolling by invitation
Conditions studied: Schizophrenia
In brief
Schizophrenia is a common, long-term mental illness. It causes problems with thoughts, feelings, and behavior, including positive symptoms (hallucinations, delusions), negative symptoms (lack of emotion, motivation), and cognitive impairment (trouble with thinking, memory, and attention). While antipsychotic drugs effectively treat positive symptoms, they don't help much with cognitive impairment.This study will examine how the tryptophan-kynurenine pathway in the brain contributes to cognitive problems in people having their first episode of schizophrenia and treated with a single antipsychotic. Our goal is to create models for early detection of cognitive impairment in schizophrenia and find potential targets for new treatments to improve thinking and memory.
Key facts
- Study ID
- NCT07162467
- Run by
- Tianjin Anding Hospital
- People needed
- 200
- Starts
- 2024-02-19
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2026-01-14
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy volunteers matched to the patient group on sex, age, and education level;
- Ethnic Han Chinese;
- Able and willing to provide written informed consent.
You may not qualify if…
- Significant comorbid medical or neurological conditions;
- Any DSM-5-defined psychiatric disorder;
- Family history of psychiatric illness spanning three or more generations;
- Current use of psychoactive medications;
- Refusal to provide informed consent/participate.
Where it is running
- Tianjin Anding Hospital — Tianjin, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.